Authorized purpose: AutoContour Model RADAC V4 assists radiation treatment planners with contouring and reviewing structures in medical images for radiation therapy treatment planning. It generates initial machine-learning contours for user review and modification rather than independently approving contours or treatment plans.
Clinical role
Receives CT or MR image sets, generates initial structure contours, supports manual or automatic rigid registration and automatic deformable registration, presents contours for review and editing, and exports DICOM RTSTRUCT, REGISTRATION, and DOSE objects for downstream treatment-planning review.
Images and patients
Radiotherapy Planning Imaging · Multi-region
Key limitation
Keep in mind: Every generated contour and registration must be reviewed and edited as needed before planning use. K242729 reports manufacturer nonclinical validation and explicitly states that no clinical studies were conducted for V4. Aggregate DSC and reviewer averages do not replace structure-level review: some model-level lower confidence bounds fall below the nominal size-category threshold, and small structures and very small external test sets remain important limitations. The summary describes training anatomy from adult male and female patients, so pediatric, postsurgical, unusual-anatomy, positioning, contrast, and local-guideline performance require local validation.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: AutoContour Model RADAC V4 assists radiation treatment planners with contouring and reviewing structures in medical images for radiation therapy treatment planning. It generates initial machine-learning contours for user review and modification rather than independently approving contours or treatment plans.
Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: Multi-region Input: DICOM CT or MR images for contouring or registration and fusion; PET/CT for registration or fusion only; and DICOM RTSTRUCT and REGISTRATION objects as supported inputs.
Who uses it?Intended users: Radiation treatment planners qualified to select, review, edit, and export contours. Local governance should assign responsibilities across radiation oncologists, dosimetrists, medical physicists, radiation therapists, and clinical IT.
What does the software produce?Output: User-reviewed and editable contours plus DICOM RTSTRUCT, REGISTRATION, and DOSE files for downstream review in a treatment-planning or independent registration-QA system. The FDA summary states that the device has no built-in reporting.
What is its most important limitation?Key limitation: Every generated contour and registration must be reviewed and edited as needed before planning use. K242729 reports manufacturer nonclinical validation and explicitly states that no clinical studies were conducted for V4. Aggregate DSC and reviewer averages do not replace structure-level review: some model-level lower confidence bounds fall below the nominal size-category threshold, and small structures and very small external test sets remain important limitations. The summary describes training anatomy from adult male and female patients, so pediatric, postsurgical, unusual-anatomy, positioning, contrast, and local-guideline performance require local validation.
Clinical takeaway. Clinical role: AutoContour Model RADAC V4 assists radiation treatment planners with contouring and reviewing structures in medical images for radiation therapy treatment planning. It generates initial machine-learning contours for user review and modification rather than independently approving contours or treatment plans.
Evidence takeaway. Evidence from the reviewed source record: V4 has an exact FDA technical-validation package and independent product-family evidence from earlier software versions. The evidence supports assisted contour generation with mandatory review; it does not establish autonomous use, universal generalizability, reduced toxicity, improved tumor control, or other patient outcomes.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
AutoContour Model RADAC V4 assists radiation treatment planners with contouring and reviewing structures in medical images for radiation therapy treatment planning. It generates initial machine-learning contours for user review and modification rather than independently approving contours or treatment plans.
Receives CT or MR image sets, generates initial structure contours, supports manual or automatic rigid registration and automatic deformable registration, presents contours for review and editing, and exports DICOM RTSTRUCT, REGISTRATION, and DOSE objects for downstream treatment-planning review.
DICOM CT or MR images for contouring or registration and fusion; PET/CT for registration or fusion only; and DICOM RTSTRUCT and REGISTRATION objects as supported inputs.
User-reviewed and editable contours plus DICOM RTSTRUCT, REGISTRATION, and DOSE files for downstream review in a treatment-planning or independent registration-QA system. The FDA summary states that the device has no built-in reporting.
Radiation treatment planners qualified to select, review, edit, and export contours. Local governance should assign responsibilities across radiation oncologists, dosimetrists, medical physicists, radiation therapists, and clinical IT.
Every generated contour and registration must be reviewed and edited as needed before planning use. K242729 reports manufacturer nonclinical validation and explicitly states that no clinical studies were conducted for V4. Aggregate DSC and reviewer averages do not replace structure-level review: some model-level lower confidence bounds fall below the nominal size-category threshold, and small structures and very small external test sets remain important limitations. The summary describes training anatomy from adult male and female patients, so pediatric, postsurgical, unusual-anatomy, positioning, contrast, and local-guideline performance require local validation.
V4 has an exact FDA technical-validation package and independent product-family evidence from earlier software versions. The evidence supports assisted contour generation with mandatory review; it does not establish autonomous use, universal generalizability, reduced toxicity, improved tumor control, or other patient outcomes.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
V4 has an exact FDA technical-validation package and independent product-family evidence from earlier software versions. The evidence supports assisted contour generation with mandatory review; it does not establish autonomous use, universal generalizability, reduced toxicity, improved tumor control, or other patient outcomes.
Sensitivity is not an applicable endpoint for this contour-generation device. Review the structure-specific DSC, distance, clinician-review, and local edit-burden evidence instead.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-02
Specificity is not an applicable endpoint for this contour-generation device. Review the structure-specific DSC, distance, clinician-review, and local edit-burden evidence instead.
New CT models versus RADAC V3
77 models
EndpointNew CT contouring models added in RADAC V4 relative to its V3 predicate
PopulationHead and neck, thorax, abdomen, and pelvis structures listed in K242729
Tested versionAutoContour Model RADAC V4 cleared in K242729
K242729 AutoContour Model RADAC V4 verification and validation
DesignManufacturer nonclinical validation using held-out training-test partitions, external CT and MR datasets, size-stratified DSC criteria, and clinical-expert Likert review
PopulationCT and MR structures across head and neck, thorax, abdomen, and pelvis, with CT data from four institutions in the United States and Switzerland and additional MR sources
Scopeexact submission
Tested versionAutoContour Model RADAC V4 cleared in K242729
IndependenceSponsor or vendor study
K242729
The FDA summary states that no clinical studies were conducted. External testing was separate from training, but the evidence was manufacturer generated and some structure-level confidence bounds were below category thresholds.
A clinical evaluation of the performance of five commercial artificial intelligence contouring systems for radiotherapy
DesignIndependent single-center multi-vendor benchmark against manually drawn expert contours with geometric metrics and correction-time measurement
Population80 patients: 20 breast, 20 head and neck, 20 lung, and 20 prostate; 45 structures
Scopeproduct family
Tested versionAutoContour v1.0.25.0 tested in April 2022
Samplen=80
Sites1
IndependenceIndependent study
PMID 37601695
The authors reported no commercial or financial conflicts and acknowledged vendor support and guidance. Timing estimates used a three-patient subset and cannot be transferred to V4 or another site.
Evaluation of multiple-vendor AI autocontouring solutions
DesignIndependent single-center blinded physician review and geometric comparison of three commercial CT autocontouring systems against approved physician contours
PopulationSixteen organs, ten patients per organ, 47 distinct patients, and at least three physician reviewers per contour
Scopeproduct family
Tested versionAutoContour v2.2.8
Samplen=47
Sites1
IndependenceIndependent study
PMID 38822385
The study found generally comparable performance but documented poor results with unusual anatomy and local contour-definition differences. It informed implementation across five facilities, but the exact relationship between v2.2.8 and RADAC V4 was not established.
Evaluation and failure analysis of four commercial deep learning-based autosegmentation software for abdominal organs at risk
DesignIndependent retrospective multi-vendor geometric evaluation with explicit outlier and failure-mode analysis
Population111 abdominal cases evaluating liver, stomach, and kidney contours
Scopeproduct family
Tested versionAutoContour v1.7.11
Samplen=111
Sites1
IndependenceIndependent study
PMID 39946266
Radformation outliers included liver spill into heart or stomach, incomplete stomach contours with barium, and kidney differences driven by whether the renal pelvis was included. The authors reported no conflicts.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K242729 by exact submission identifier.
Public source
Exact FDA submission
Checked 2026-09-02
A zero-result exact-identifier search does not prove that no recall, correction, MAUDE report, or other safety signal exists under a model, catalog, software-version, or product-family identifier. Maintain ongoing FDA and vendor surveillance.
Pricing is recorded, but no exact-product procurement price with a stated offer scope is published in the reviewed sources.
Public pricing
No public list price for AutoContour Model RADAC V4 was found on the reviewed product page. Radformation's current license agreement places fees in a customer quote, treats pricing as confidential, and permits additional charges for special support. A V4 support or upgrade quote should separate licensing, implementation, compute, storage, network needs, training, support, upgrade, renewal, and end-of-support terms.
No separate named-product Medicare payment for AutoContour was identified in the reviewed CMS Radiation Oncology Model material. Economic value should be evaluated within the radiation-therapy planning service line using net staff time saved after review and editing, implementation and recurring costs, throughput effects, rework, and downstream plan-quality measures.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM CT or MR images for contouring or registration and fusion; PET/CT for registration or fusion only; and DICOM RTSTRUCT and REGISTRATION objects as supported inputs.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA-cleared architecture uses DICOM data, a Windows .NET client, a Windows agent that can monitor network storage for new CT or MR datasets, and a Linux-compatible cloud contouring service. V4 can export DICOM deformable REGISTRATION and deformed DOSE objects for review in external treatment-planning and registration-QA systems. Current product-family materials also describe direct Eclipse read/write and standalone DICOM workflows.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: K242729 describes a Windows .NET client and local Windows agent connected to a Linux-compatible cloud automatic-contouring service. Current product-family materials also offer cloud-based or local compute resources, but the V4 summary does not establish that every current deployment option applies to this cleared version.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: User-reviewed and editable contours plus DICOM RTSTRUCT, REGISTRATION, and DOSE files for downstream review in a treatment-planning or independent registration-QA system. The FDA summary states that the device has no built-in reporting.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: User-reviewed and editable contours plus DICOM RTSTRUCT, REGISTRATION, and DOSE files for downstream review in a treatment-planning or independent registration-QA system. The FDA summary states that the device has no built-in reporting.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
K242729 describes a Windows .NET client and local Windows agent connected to a Linux-compatible cloud automatic-contouring service. Current product-family materials also offer cloud-based or local compute resources, but the V4 summary does not establish that every current deployment option applies to this cleared version.
The FDA-cleared architecture uses DICOM data, a Windows .NET client, a Windows agent that can monitor network storage for new CT or MR datasets, and a Linux-compatible cloud contouring service. V4 can export DICOM deformable REGISTRATION and deformed DOSE objects for review in external treatment-planning and registration-QA systems. Current product-family materials also describe direct Eclipse read/write and standalone DICOM workflows.
Radformation's current license terms state that cloud-processing configurations transmit selected CT or MR images, structures, plan, and dose data after software anonymization, encrypt the data in transit, and delete the imaging-plan data after returning results. The customer remains responsible for preventing PHI disclosure. The reviewed public sources do not establish which current controls apply to an installed V4 environment or describe its authentication, at-rest encryption, retention logging, vulnerability, backup, and incident-response controls.
Product family
Checked 2026-09-02
Obtain version-specific security and support evidence and validate anonymization, identity, access, encryption, logging, deletion, recovery, and breach-response behavior.
Radformation's current support terms include online educational materials, videos, and a remote training session with new access. NICE states that trained professionals must always review and edit AI autocontours and maintain manual contouring skills. Local V4 training should cover model selection, contouring-guideline alignment, review and editing, unusual-anatomy failure modes, registration QA, DICOM routing, downtime, and escalation.
Monitor performance by exact software and model version, anatomy, structure, scanner and protocol, patient position, contrast, unusual or postsurgical anatomy, reviewer role, edit time, unusable or missing contours, DICOM transfer failures, registration and dose-export QA, incidents, and adverse events. NICE calls for ongoing error and adverse-event reporting, while independent AutoContour studies show that geometric averages can conceal clinically important outliers and contour-definition mismatches.
Product family
Checked 2026-09-02
Define signed acceptance thresholds and revalidation triggers for software, model, scanner, protocol, routing, or local contouring-guideline changes.
K242729 adds 77 CT and 18 MR contouring models to the V3 predicate across head and neck, thorax, abdomen, and pelvis and retains user review and editing.
exact submission · checked 2026-09-02
Create an enabled-model inventory tied to the installed build, FDA labeling, local anatomy, local contour definitions, and acceptance status.
The exact FDA architecture supports CT and MR contouring, PET/CT registration or fusion, DICOM RTSTRUCT and REGISTRATION inputs, and RTSTRUCT, REGISTRATION, and DOSE exports. Current product-family materials describe direct Eclipse and standalone DICOM workflows.
exact submission · checked 2026-09-02
Test each scanner, TPS, service class, object mapping, frame of reference, naming rule, routing path, retry, and failure-recovery workflow.
The device produces initial contours for review and modification. NICE and independent studies support model-by-model commissioning, trained review, retained manual skills, and special attention to small structures, unusual anatomy, contrast, positioning, and local contouring conventions.
product family · checked 2026-09-02
Commission with representative local cases and predefine accept, edit, reject, and manual-fallback criteria for each enabled model.
Current terms describe software anonymization, encrypted transmission, processing by Radformation, return of results, and deletion of imaging-plan data, while making the customer responsible for preventing PHI disclosure.
product family · checked 2026-09-02
Confirm the terms and controls that apply to the installed V4 environment and validate DICOM private tags, burned-in annotations, logs, support access, deletion evidence, and exception handling.
The vendor uses quote-based licensing. NICE found autocontouring economics depend on technology cost, professional grade, review and edit time, and true net time saved, with published time endpoints varying substantially.
product family · checked 2026-09-02
Model costs per completed plan and measure total hands-on and elapsed time, edit burden, rejected contours, downstream rework, throughput, and avoided overtime.
Current support terms condition support on current releases and installed updates. V4 users should obtain explicit support status, security-update commitments, migration scope, data portability, regression requirements, and rollback terms.
product family · checked 2026-09-02
Treat migration to a later model family as a controlled clinical change rather than assuming prior acceptance transfers.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-20Last searched
25Fields reviewed
13Source classes checked
20Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 20 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 20 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, vendor product page, vendor legal documentation, peer reviewed publication, health technology guidance, trial registry, reimbursement policy, fda device recall, literature index, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Authorized purpose: AutoContour Model RADAC V5 assists radiation treatment planners with contouring and reviewing structures in medical images for radiation therapy treatment planning. It produces initial machine-learning contours for user review and modification; it does not independently approve a contour or treatment plan.
Authorized purpose: The EMLA family delivers external-beam radiation therapy for adult and pediatric patients with benign, malignant, or metastatic disease. Authorized techniques vary by model: Synergy and Harmony include conventional and fractionated delivery; Infinity and Harmony Pro add SBRT/SABR; Versa HD and Evo also support SRS and specified functional disorders.
Authorized purpose: ART-Plan+ assists trained radiation-therapy professionals with multimodal image review, registration, contouring, and the release-specific planning functions described in K253091. This release combined Annotate, prostate SmartPlan, and AdaptBox for supported head-and-neck, breast or thorax, and male-pelvis offline adaptive workflows, and added structures without changing the core indication.
Authorized purpose: Oncospace supports trained radiation therapy professionals with protocol configuration, machine-learning achievable-dose prediction, planning-objective exchange, and plan review across head-and-neck, thoracic, abdominal, and pelvic workflows using locked models.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.